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Of the more than 2,000 high-production
volume chemicals that are manufactured in or
imported into the United States in amounts of
one million pounds or more per year (U.S.
Environmental Protection Agency 2004),
many are widely used in consumer products.
Among these chemicals are bisphenol A [BPA;
2,2-bis(4-hydroxyphenyl)propane; CAS no.
80-05-7] and 4-tertiary-octylphenol [tOP;
4-(1,1,3,3-tetramethylbutyl)phenol; CAS no.
140-66-9]. BPA is used in the manufacture of
polycarbonate plastic and epoxy resins, which
can be used in impact-resistant safety equip-
ment and baby bottles, as protective coatings
inside metal food containers, and as compos-
ites and sealants in dentistry [Center for the
Evaluation of Risks to Human Reproduction
(CERHR) 2007; European Union 2003].
Exposure to BPA is thought to result primarily
from ingestion of food containing BPA (Kang
et al. 2006; Vandenberg et al. 2007). tOP is
both a degradation product of and an interme-
diate in the manufacture of octylphenol
ethoxylates, which are nonionic surfactants
used in detergents, pesticide formulations, and
other applications (Ying et al. 2002). Exposure
to tOP may occur from contact with personal
care products, detergents, water, and food
containing tOP.
Exposures to tOP can result in develop-
mental and reproductive alterations in aquatic
species (Segner et al. 2003) and in laboratory
animals (Aydogan and Barlas 2006; Bian et al.
2006; Blake et al. 2004; Nagao et al. 2001;
Willoughby et al. 2005). At high doses, BPA
demonstrates estrogen-like effects on uterine
and prostate organ weights in experimental
animals. At doses below the putative lowest
observed adverse effect level, exposure to BPA
has reportedly resulted in decreased sperm
production, increased prostate gland volume,
altered development and tissue organization of
the mammary gland, altered vaginal morphol-
ogy and estrous cycles, disruption of sexual
differentiation in the brain, and accelerated
growth and puberty (Durando et al. 2007;
Howdeshell et al. 1999; Kubo et al. 2003;
Richter et al. 2007; Rubin et al. 2006;
Schonfelder et al. 2002; Timms et al. 2005;
vom Saal et al. 1998). At present, the interpre-
tation of the evidence related to the low-dose
effects of BPA is a subject of scientiﬁc debate
(European Union 2003; Goodman et al.
2006; Gray et al. 2004; National Toxicology
Program 2001; vom Saal and Hughes 2005). 
BPA and tOP are of concern to environ-
mental public health because of the high
potential for exposure of humans to these
phenols and their demonstrated animal toxic-
ity. Information about the concentrations of
these compounds in the general population is
important for understanding human exposure
to BPA and tOP. The National Health and
Nutrition Examination Survey (NHANES),
conducted continuously since 1999 by the
National Center for Health Statistics of the
Centers for Disease Control and Prevention
(CDC), is designed to measure the health and
nutritional status of the civilian noninstitu-
tionalized U.S. population ≥ 2 months of age
(CDC 2003). The surveys include household
interviews; collection of medical histories;
standardized physical examinations; and col-
lection of biologic specimens (e.g., blood and
urine from participants ≥ 1 and ≥ 6 years of
age, respectively) for clinical chemistry test-
ing, nutritional indicators assessments, and
assessment of exposure to environmental
chemicals (CDC 2005, 2006). 
Previously, we analyzed 394 urine samples
collected from adult participants of NHANES
III, conducted during 1988–1994, to estimate
urinary concentrations of total BPA (free plus
conjugated species) in selected demographic
groups (Calafat et al. 2005). We now report the
ﬁrst estimate of urinary concentrations of total
BPA and tOP in NHANES 2003–2004 partic-
ipants, a representative sample of the noninsti-
tutionalized U.S. population ≥ 6 years of age. 
Materials and Methods
NHANES participants are selected based on
their age, sex, and racial/ethnic background
through a complex statistical process using
the most current census information. Persons
on full-time active duty with the U.S. armed
forces are not eligible to participate (CDC
2006). Urine samples analyzed in this study
were obtained from 2,517 people, a one-third
random subset of participants in NHANES
2003–2004. The National Centers for Health
Statistics Institutional Review Board reviewed
and approved the study protocol. Informed
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BACKGROUND: Bisphenol A (BPA) and 4-tertiary-octylphenol (tOP) are industrial chemicals used
in the manufacture of polycarbonate plastics and epoxy resins (BPA) and nonionic surfactants
(tOP). These products are in widespread use in the United States. 
OBJECTIVES: We aimed to assess exposure to BPA and tOP in the U.S. general population.
METHODS: We measured the total (free plus conjugated) urinary concentrations of BPA and tOP in
2,517 participants ≥ 6 years of age in the 2003–2004 National Health and Nutrition Examination
Survey using automated solid-phase extraction coupled to isotope dilution–high-performance liquid
chromatography–tandem mass spectrometry.
RESULTS: BPA and tOP were detected in 92.6% and 57.4% of the persons, respectively. Least
square geometric mean (LSGM) concentrations of BPA were significantly lower in Mexican
Americans than in non-Hispanic blacks (p = 0.006) and non-Hispanic whites (p = 0.007); LSGM
concentrations for non-Hispanic blacks and non-Hispanic whites were not statistically different
(p = 0.21). Females had statistically higher BPA LSGM concentrations than males (p = 0.043).
Children had higher concentrations than adolescents (p < 0.001), who in turn had higher concen-
trations than adults (p = 0.003). LSGM concentrations were lowest for participants in the high
household income category (> $45,000/year).
CONCLUSIONS: Urine concentrations of total BPA differed by race/ethnicity, age, sex, and house-
hold income. These ﬁrst U.S. population representative concentration data for urinary BPA and
tOP should help guide public health research priorities, including studies of exposure pathways,
potential health effects, and risk assessment.
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24 October 2007]written consent was obtained from all partici-
pants; parents or guardians provided consent
for participants < 18 years of age. 
One spot urine sample per participant was
collected during one of three daily examination
session periods (i.e., morning, afternoon,
evening). We measured the total urinary con-
centrations (free plus conjugated species) of
BPA and tOP using online solid-phase extrac-
tion (SPE) coupled to high-performance liquid
chromatography (HPLC)–isotope dilution tan-
dem mass spectrometry (MS/MS) with peak
focusing as described before (Ye et al. 2005).
Brieﬂy, the conjugated species of BPA and tOP
in 100 µL urine were hydrolyzed by use of β-
glucuronidase/sulfatase (Helix pomatia H1;
Sigma Chemical Co., St. Louis, MO). After
hydrolysis, samples were acidiﬁed with 0.1 M
formic acid; BPA and tOP were preconcen-
trated by online SPE, separated by reversed-
phase HPLC, and detected by atmospheric
pressure chemical ionization–MS/MS. The lim-
its of detection (LODs) were 0.4 µg/L (BPA)
and 0.2 µg/L (tOP). The LOD, calculated as
3S0, where S0 is the standard deviation as the
concentration approaches zero, is the concen-
tration at which a measurement has a 95%
probability of being greater than zero (Taylor
1987). Depending on the concentration, the
coefﬁcients of variation ranged from 11% to
13% for BPA and from 17% to 25% for tOP
[Supplemental Material, Table 1 (online at
http://www.ehponline.org/members/
2007/10753/suppl.pdf)]. Low-concentration (~
4 µg/L) and high-concentration (~ 20 µg/L)
quality control materials, prepared with pooled
human urine spiked with the analytes of inter-
est, were analyzed with standard, reagent blank,
and NHANES samples.
We performed statistical analyses using
SAS (version 9.1.3; SAS Institute Inc., Cary,
NC) and SUDAAN (version 9.0.1; RTI
International, Research Triangle Park, NC).
SUDAAN calculates variance estimates after
incorporating the sample population weights,
which account for unequal selection probabili-
ties and planned oversampling of certain sub-
groups resulting from the complex multistage
probability design of NHANES. We calcu-
lated geometric means (if the overall weighted
frequency of detection was > 60%) and distri-
bution percentiles for both volume-based
(micrograms per liter) and creatinine-
corrected concentrations (micrograms per
gram creatinine). For concentrations below
the LOD, a value equal to the LOD divided
by the square root of 2 was used in the uni-
variate and multivariate analyses (Hornung
and Reed 1990). Because the concentrations
of BPA and tOP were not normally distrib-
uted, we used their naturallog transformation.
We used analysis of covariance to examine
how well selected variables were associated
with the log-transformed urine concentra-
tions of BPA. Age, reported in years at the last
birthday, was categorized in four groups
(6–11, 12–19, 20–59, and ≥ 60 years).
Participants were categorized as smokers if
their serum cotinine concentrations were > 10
µg/L. Only 6% of children and adolescents
(and nobody < 11 years of age) were consid-
ered smokers. On the basis of self-reported
data, we categorized race/ethnicity into three
groups: non-Hispanic blacks, non-Hispanic
whites, and Mexican Americans. Persons not
included in one of these three race/ethnicity
groups were included only in the total popula-
tion estimate. Also on the basis of question-
naire responses, annual household income was
available in increments of $5,000 (ranging
from < $5,000 to > $75,000). To obtain com-
parable number of participants per income
group, we categorized income as < $20,000,
$20,000–$45,000, and > $45,000. We con-
sidered all possible two-way interactions. For
the multiple regression analyses, we calculated
the least square geometric mean (LSGM)
concentrations of BPA and compared them
for each categorical variable. The multiple
regression analysis was initially conducted
separately for children and adolescents (6–19
years of age) and adults (≥ 20 years of age)
with age as continuous variable and smoking
status included only for the adult model. We
did not include smoking status in the chil-
dren and adolescents model because of the
small proportion and uneven distribution of
smokers among these two groups. For chil-
dren and teens, body mass index (BMI) is
both age- and sex-specific, and instead of
BMI we used BMI-for-age percentile
(BMIPCT), calculated on the basis of a BMI-
for-age growth chart for persons 2–19 years of
age (Kuczmarski et al. 2002). Because neither
BMI nor smoking status in the adult model
nor BMIPCT in the model for children and
teens were significantly associated with BPA
concentrations, these variables were not
included in analysis of all ages combined.
Because the distribution of creatinine concen-
trations was skewed, we used their common
log transformation. 
To arrive at the final model, we used
backward elimination with SUDAAN to
eliminate the nonsigniﬁcant interactions one
at a time. Then we removed nonsignificant
main effects one at a time and reran the
model to determine whether the beta coeffi-
cients for significant main effects or interac-
tions changed by > 10%. If any did, we
retained the nonsigniﬁcant main effect in the
model. Once the backward procedure was
completed, main effects and interactions were
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Table 1. Geometric mean and selected percentiles of bisphenol A (BPA) concentrations [µg/L (95% CI)] in urine for the U.S. population ≥ 6 years of age.a
Variable Geometric mean 10thpercentile 25thpercentile 50thpercentile 75th percentile 90th percentile 95th percentile No.
All 2.6 (2.4–2.9) 0.5 (< LOD–0.6) 1.3 (1.1–1.5) 2.7 (2.4–3.0) 5.4 (5.0–6.1) 10.4 (9.4–12.0) 15.9 (14.4–17.2) 2,517
2.6 (2.4–2.8) 0.9 (< LOD–1.0) 1.5 (1.3–1.7) 2.5 (2.3–2.8) 4.3 (3.9–4.7) 7.7 (6.6–8.7) 11.2 (9.8–12.4) 2,514
6–11 years 3.6 (2.9–4.3) 0.9 (0.7–1.1) 1.7 (1.2–2.5) 3.7 (2.7–5.0) 6.7 (6.0–8.3) 12.6 (9.5–15.1) 16.0 (11.3–19.0) 314
4.3 (3.6–5.1) 1.3 (1.2–1.7) 2.7 (1.7–3.3) 4.2 (3.6–5.2) 7.1 (5.8–9.6) 11.8 (9.8–14.8) 15.7 (12.2–23.2) 314
12–19 years 3.7 (3.3–4.2) 0.8 (0.5–1.3) 1.9 (1.6–2.3) 4.2 (3.6–4.6) 7.5 (6.5–9.0) 13.5 (11.8–15.2) 16.5 (15.2–20.9) 715
2.8 (2.5–3.1) 1.0 (0.9–1.1) 1.7 (1.5–1.9) 2.7 (2.4–3.2) 4.7 (4.2–5.1) 7.8 (6.4–8.9) 11.4 (8.1–14.2) 713
20–59 years 2.6 (2.3–2.9) 0.5 (< LOD–0.6) 1.2 (1.0–1.5) 2.7 (2.4–3.0) 5.2 (4.6–6.0) 9.8 (8.1–12.1) 15.5 (12.5–19.4) 951
2.4 (2.2–2.6) 0.9 (< LOD–1.0) 1.5 (1.3–1.7) 2.4 (2.2–2.5) 3.9 (3.5–4.3) 6.6 (6.0–7.6) 9.8 (8.5–11.2) 950
≥ 60 years 1.9 (1.6–2.3) < LOD 0.8 (0.6–1.1) 1.9 (1.6–2.1) 4.1 (3.2–5.2) 8.2 (6.0–11.0) 13.3 (8.9–19.1) 537
2.3 (1.9–2.6) < LOD 1.3 (1.1–1.6) 2.2 (1.8–2.6) 3.9 (3.2–4.9) 6.9 (5.7–8.9) 12.1 (8.5–14.0) 537
Female 2.4 (2.1–2.8) < LOD 1.2 (0.8–1.4) 2.4 (2.2–2.8) 5.0 (4.2–6.2) 10.6 (8.6–12.5) 15.7 (13.5–20.1) 1,288
2.8 (2.5–3.1) < LOD 1.7 (1.5–1.8) 2.7 (2.4–2.9) 4.4 (3.8–5.2) 7.9 (6.5–10.2) 12.2 (9.3–18.1) 1,286
Male 2.9 (2.6–3.2) 0.7 (0.5–0.8) 1.4 (1.2–1.6) 3.2 (2.7–3.5) 6.1 (5.4–6.6) 10.4 (9.5–11.4) 16.0 (12.7–17.2) 1,229
2.4 (2.1–2.6) 0.8 (0.7–1.0) 1.4 (1.2–1.6) 2.3 (2.1–2.7) 4.2 (3.8–4.6) 7.1 (6.4–8.3) 9.9 (9.1–11.7) 1,228
Mexican American 2.6 (2.2–3.1) 0.6 (0.4–0.7) 1.3 (1.0–1.6) 2.6 (2.0–3.1) 5.2 (4.4–6.5) 9.8 (7.3–13.9) 15.4 (10.2–19.7) 613
2.3 (2.0–2.7) 0.8 (0.5–1.1) 1.4 (1.2–1.6) 2.4 (2.0–2.7) 3.9 (3.2–4.6) 7.1 (5.0–9.0) 10.7 (8.5–14.3) 612
Non-Hispanic black 4.2 (3.7–4.8) 1.2 (0.9–1.3) 2.3 (1.8–2.7) 4.2 (3.7–5.1) 8.1 (7.1–9.7) 14.1 (11.7–16.9) 20.5 (14.9–25.2) 652
2.9 (2.6–3.3) 0.9 (0.8–1.3) 1.7 (1.4–2.1) 3.0 (2.5–3.3) 4.9 (4.1–6.1) 8.6 (7.5–9.6) 11.8 (10.2–13.3) 651
Non-Hispanic white 2.5 (2.3–2.8) 0.5 (< LOD–0.6) 1.2 (0.9–1.4) 2.7 (2.4–2.8) 5.1 (4.7–5.8) 9.5 (8.3–10.9) 15.1 (12.6–16.7) 1,092
2.6 (2.4–2.8) 0.9 (< LOD–1.1) 1.5 (1.3–1.7) 2.6 (2.3–2.8) 4.3 (3.9–4.7) 7.6 (6.3–8.9) 11.0 (9.3–12.4) 1,091
CI, conﬁdence interval. Data are from NHANES 2003–2004. Blue lines denote measure in µg/g creatinine. 
aPersons not deﬁned by these three race/ethnicity groups were included only in the total population estimate. LOD = 0.4 µg/L. The weighted frequency of detection was 92.6%.added back into the model one at a time
to determine whether any were significant
(p < 0.05). If any were, they were retained in
the ﬁnal model.
We also compared the geometric mean
concentrations of BPA by examination session
(i.e., morning, afternoon, evening) for all ages
and stratiﬁed by age (i.e., children and adoles-
cents, adults).
Results
BPA was detected in 92.6% of persons ≥ 6 years
of age with total concentrations ranging from
0.4 µg/L to 149 µg/L. tOP was detected in
57.4% of samples at total concentrations of
0.2 µg/L–20.6 µg/L (Tables 1 and 2). For BPA,
the geometric mean and 95th percentile con-
centrations were 2.6 µg/L (2.6 µg/g creatinine)
and 15.9 µg/L (11.2 µg/g creatinine), respec-
tively. For tOP, the 95th percentile concentra-
tion was 2.2 µg/L (2.8 µg/g creatinine); because
the overall weighted frequency of detection was
< 60%, we did not calculate the geometric
mean or conduct multivariate analysis.
In the regression model for BPA for all
ages, we included sex, race/ethnicity, age
group, household income, and creatinine
concentration (Barr et al. 2005) as indepen-
dent variables. The final model included sex
(p = 0.04), race/ethnicity (p = 0.02), age
group (p < 0.01), creatinine concentration
(p < 0.01), and income (p = 0.02). The
LSGM concentrations (Tables 3 and 4),
which provide geometric mean estimates for a
demographic variable after adjustment for the
model covariates, were significantly lower in
Mexican Americans than in non-Hispanic
blacks (p = 0.006) and non-Hispanic whites
(p = 0.007); the difference was not statistically
signiﬁcant between non-Hispanic blacks and
non-Hispanic whites (p = 0.21). Females had
statistically higher LSGM concentrations than
did males (p = 0.043). LSGM concentrations
of BPA for those in the low household
income category were higher than for those in
the high category (p = 0.004; Tables 3 and 4).
Children had higher LSGM BPA concentra-
tions than adolescents (p < 0.001), who in
turn had higher concentrations than adults
(p = 0.003) (Tables 3 and 4). 
We compared the geometric mean BPA
concentrations by examination session time,
and separately for adults and for children and
adolescents (Figure 1). The geometric mean
concentrations of BPA were significantly
higher in the morning than in the afternoon
collections for all ages (p = 0.0134) and for
adults (p = 0.015), but not for children and
adolescents (p = 0.18). Similarly, the geomet-
ric mean concentrations of BPA were signiﬁ-
cantly higher in the evening than in the
afternoon collections for all ages (p = 0.0317),
but not for children and adolescents (p = 0.2),
and only marginally different for adults (p =
0.06). The geometric mean concentrations
of BPA between the morning and evening
sessions were not significantly different
[Supplemental Material, Table 2 (online at
http://www.ehponline.org/members/2007/
10753/suppl.pdf)]. When we included exami-
nation session time as an independent vari-
able, in addition to sex, race/ethnicity, age
group, household income, and creatinine
concentration, the ﬁnal regression model for
BPA for all ages, yielded comparable results
plus one additional race/ethnicity-by-
examination session time interaction term
[Supplemental Material, Tables 3–4 (online
at http://www.ehponline.org/members/2007/
10753/suppl.pdf)].
Discussion 
The free plus conjugated (total) urinary species
of BPA were detected in 92.6% of persons
≥ 6 years of age in this sample of the U.S.
population. In humans, orally administered
BPA is conjugated to the monoglucuronide
and excreted (Volkel et al. 2002), with an
Human exposure to bisphenol A and 4-tertiary-octylphenol
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Table 2. Selected percentiles of tOP concentrations [µg/L (95% CI)] in urine for the U.S. population ≥ 6 years of age.a
Variable 10thpercentile 25thpercentile 50thpercentile 75th percentile 90th percentile 95th percentile No.
All < LOD < LOD 0.3 (< LOD–0.4) 0.9 (0.5–1.2) 1.6 (1.1–2.2) 2.2 (1.6–3.2) 2,517
< LOD < LOD 0.3 (< LOD–0.5) 0.9 (0.6–1.3) 1.9 (1.3–2.5) 2.8 (2.0–4.0) 2,514
6–11 years < LOD < LOD 0.4 (0.2–0.5) 0.8 (0.5–1.4) 1.6 (1.1–2.1) 2.0 (1.5–2.9) 314
< LOD < LOD 0.5 (0.3–0.6) 1.1 (0.7–1.6) 2.0 (1.7–2.2) 2.4 (2.0–6.0) 314
12–19 years < LOD < LOD 0.4 (0.2–0.5) 1.1 (0.6–1.5) 1.7 (1.2–2.4) 2.4 (1.6–3.2) 715
< LOD < LOD 0.3 (0.2–0.5) 0.7 (0.5–1.2) 1.6 (1.1–2.6) 2.6 (1.5–3.7) 713
20–59 years < LOD < LOD 0.2 (< LOD–0.4) 0.7 (0.5–1.2) 1.7 (1.1–2.3) 2.2 (1.5–3.4) 951
< LOD < LOD 0.3 (< LOD–0.4) 0.8 (0.5–1.1) 1.6 (1.1–2.7) 2.7 (1.6–3.7) 950
60 years < LOD < LOD 0.3 (< LOD–0.4) 1.0 (0.7–1.4) 1.7 (1.1–2.2) 2.4 (1.6–2.9) 537
< LOD < LOD 0.4 (< LOD–0.7) 1.2 (0.8–1.7) 2.4 (1.7–3.2) 3.3 (2.3–5.3) 537
Female < LOD < LOD 0.2 (< LOD–0.4) 0.9 (0.5–1.2) 1.6 (1.1–2.3) 2.3 (1.5–2.9) 1,288
< LOD < LOD 0.4 (< LOD–0.6) 1.0 (0.6–1.4) 2.2 (1.4–3.0) 3.3 (2.4–4.8) 1,286
Male < LOD < LOD 0.3 (< LOD–0.4) 0.9 (0.5–1.5) 1.8 (1.2–2.4) 2.2 (1.6–3.2) 1,229
< LOD < LOD 0.3 (< LOD–0.4) 0.7 (0.5–1.1) 1.6 (1.1–2.3) 2.4 (1.6–3.3) 1,228
Mexican American < LOD < LOD < LOD 0.5 (0.3–0.6) 0.8 (0.6–1.3) 1.3 (0.8–1.8) 613
< LOD < LOD < LOD 0.4 (0.3–0.6) 0.9 (0.6–1.4) 1.6 (0.9–2.7) 612
Non-Hispanic black < LOD < LOD 0.4 (< LOD–0.5) 1.0 (0.7–1.4) 1.9 (1.3–2.6) 2.4 (1.6–3.1) 652
< LOD < LOD 0.3 (< LOD–0.4) 0.8 (0.5–1.1) 1.5 (1.1–2.1) 2.3 (1.7–2.8) 651
Non-Hispanic white < LOD < LOD 0.3 (< LOD–0.5) 0.9 (0.6–1.5) 1.7 (1.2–2.4) 2.3 (1.6–3.3) 1,092
< LOD < LOD 0.4 (< LOD–0.6) 1.0 (0.6–1.4) 2.0 (1.4–3.0) 3.1 (2.2–4.2) 1,091
CI, conﬁdence interval. Data are from NHANES 2003–2004. Blue lines denote measure in µg/g creatinine.
aThe geometric mean was not calculated because the overall weighted frequency of detection was < 60% (57.4%). Persons not defined by these three race/ethnicity groups were
included only in the total population estimate. LOD = 0.2 µg/L.
Table 3. Adjusted LSGM concentrations (95% conﬁ-
dence intervals) of BPA (µg/L) in various demo-
graphic groups.
Variable LSGM (95% CI)
Sex
Male 2.6 (2.4–2.8)
Female 2.9 (2.6–3.2)
Race/ethnicity
Mexican American 2.3 (2.0–2.7)
Non-Hispanic white 2.7 (2.5–2.9)
Non-Hispanic black 3.0 (2.6–3.4)
Age (years)
6–11 4.5 (3.9–5.1)
12–19 3.0 (2.7–3.4)
≥ 20 2.5 (2.3–2.7)
Income 
< $20,000 3.1 (2.7–3.5)
$20,000–$45,000 2.8 (2.6–3.1)
> $45,000 2.5 (2.3–2.7)
Table 4. Observed statistical significance values
for differences between adjusted LSGM concen-
trations of BPA for various demographic groups.
Difference p-Value
Females vs. males 0.043
Mexican Americans vs. non-Hispanic whites 0.007
Mexican Americans vs. non-Hispanic blacks 0.006
Non-Hispanic whites vs. non-Hispanic blacks 0.21
Children vs. adolescents < 0.001
Children vs. adults < 0.001
Adolescents vs. adults 0.003
< $20,000 vs. $20,000–$45,000 0.17
< $20,000 vs. > $45,000 0.004
$20,000–$45,000 vs. > $45,000 0.088estimated half-life of BPA of ~ 6 hr (CERHR
2007). Taken together, these data suggest con-
tinual exposure to BPA. After human expo-
sure, a fraction of the absorbed BPA may
distribute to body storage site(s) (such as adi-
pose tissue) (Fernandez et al. 2007), followed
by a slow release into the bloodstream and ulti-
mately into the urine. This would result in a
low-dose continuous exposure within the
body, similar to that proposed for the insecti-
cide chlorpyrifos (Needham 2005). BPA stored
in adipose tissue likely would be in its more
lipophilic free form rather than in its
hydrophilic conjugates. If the free form is the
pharmacologically active species, one question
of public health interest is how much of the
free BPA is available to interact at the target
organ(s). The concentrations of free BPA in
circulating blood rather than the total urinary
concentrations of BPA would be especially
helpful for this assessment. Nevertheless, the
NHANES 2003–2004 urinary data suggest
that exposure to BPA is prevalent in the U.S.
general population and can be used to estimate
the distribution of BPA exposures (e.g., using
reverse dosimetry) or the daily intake (assum-
ing a steady state excretion). Furthermore,
although within-person variability in urinary
concentrations of BPA exists (Arakawa et al.
2004; Mahalingaiah et al. 2007; Teitelbaum
et al. 2007), concentrations based on one spot
sample per person can be useful in calculating
mean population concentration estimates in
cross-sectional studies (CERHR 2007).
Furthermore, data from a recent study includ-
ing about 80 adults suggest that a single sample
is predictive of BPA exposure over weeks to
months, and can provide good sensitivity to
classify a person’s exposure in epidemiologic
studies (Mahalingaiah et al. 2007). Similarly,
results from another study conducted among a
group of 35 children suggest that BPA concen-
trations in a single urine sample can be used to
categorize the 6-month average exposure to
BPA (Teitelbaum et al. 2007). 
The total concentrations of tOP were
detected in only 57.4% of persons ≥ 6 years of
age. BPA concentrations were higher than those
for tOP. The concentrations (median, 0.3 µg/L)
and frequency of detection of tOP are consis-
tent with previous limited biomonitoring data.
In 10 healthy adult (21–28 years of age)
Japanese volunteers, the urinary concentra-
tions of tOP were < 0.3 µg/L (Inoue et al.
2003). tOP was measured in five urine and
three plasma samples from eight healthy adult
(22–25 years of age) Japanese volunteers; tOP
concentrations were < 0.02 µg/L (urine) and
0.1–0.2 µg/L (plasma) (Kawaguchi et al.
2004). tOP was detected at concentrations of
< 0.05 to 1.15 µg/L in 31 of 180 human cord
blood samples collected during delivery at the
University Malaya Medical Centre in Malaysia
(Tan and Mohd 2003). 
The lower frequency of detection of tOP
than of BPA in the NHANES 2003–2004
population might be explained by lower expo-
sures to tOP or octylethoxylates (the environ-
mental precursors of tOP) than to BPA
and/or by differences in toxicokinetic factors.
After oral ingestion, BPA is rapidly metabo-
lized to BPA monoglucuronide and excreted
(Pottenger et al. 2000; Volkel et al. 2002).
In vitro (Pedersen and Hill 2000a, 2000b)
and in vivo studies in ﬁsh (Pedersen and Hill
2002) suggest that metabolism of tOP results
in a large number of metabolic products,
including oxidative metabolites. Oxidative
pathways have not been described for
humans, but, if present, tOP in urine may
not be the most sensitive biomarker of expo-
sure. Oxidative metabolites are the major uri-
nary metabolites in humans for some other
xenobiotics containing long chain alkyl moi-
eties, including the structurally related
4-nonyl phenol (Ye et al. 2007) and phthalate
diesters, such as di-isononyl phthalate and
di-(2-ethylhexyl) phthalate (Koch and
Angerer 2007; Koch et al. 2005). Research is
needed to identify and characterize tOP
oxidative metabolites that could be used to
assess exposure to tOP in humans.
In the last decade, data on the urinary con-
centrations of BPA in selected populations of
various countries have become available
(Arakawa et al. 2004; Calafat et al. 2005;
Fujimaki et al. 2004; Kim et al. 2003; Liu
et al. 2005; Matsumoto et al. 2003; Miyamoto
and Kotake 2006; Ouchi and Watanabe 2002;
Volkel et al. 2005; Wolff et al. 2007; Yang
et al. 2003, 2006). These data suggest that
human exposure to BPA is widespread
(CERHR 2007 and references therein).
However, the urinary concentrations of BPA
measured in several population groups show
some variation. For example, the median uri-
nary concentration of BPA-glucuronide,
detected in all samples collected from 48
female Japanese college students, was 1.2 µg/L
(0.77 µg/g creatinine) (Ouchi and Watanabe
2002). By contrast, concentrations of BPA uri-
nary species in seven males and 12 females in
Germany were below the LOD of 1.14 µg/L
(Volkel et al. 2005), whereas the geometric
mean concentration of BPA urinary species in
a group of 73 adult Koreans (53% female) was
9.54 µg/L (8.91 µg/g creatinine) (Yang et al.
2003). Although differences in the exposure to
BPA may exist geographically, the differences
also could be attributed at least partly to differ-
ences in timing of urine collection [between
1000 and 1900 hours (Volkel et al. 2005) or
before breakfast (Yang et al. 2003)] and analyt-
ical detection methods [coulometry (Ouchi
and Watanabe 2002), isotope dilution–tandem
mass spectrometry (Volkel et al. 2005), or
ﬂuorescence spectroscopy (Yang et al. 2003)].
We previously reported the urinary
concentrations of free plus conjugated species
of BPA in 394 adult participants in the
NHANES III callback convenience subsample
of about 1,000 persons (Calafat et al. 2005).
We detected BPA in 95% of the samples with
a geometric mean of 1.3 µg/L (Calafat et al.
2005). The frequency of detection of BPA was
similar among the NHANES III callback sub-
sample and NHANES 2003–2004. However,
the geometric mean of BPA in the NHANES
2003–2004 population was almost double that
in the NHANES III callback study population.
These differences may be related partly to the
small sample size and the not nationally repre-
sentative nature of the NHANES III callback
subsample or to the exclusion of children and
adolescents in the NHANES III callback sub-
sample, especially because concentrations of
BPA are higher in children and teens than in
adults in NHANES 2003–2004 (Table 3).
Although exposure to BPA (reflected in ele-
vated urinary concentrations of BPA) truly
might have increased since the NHANES III
1988–1994 sampling, because of the impor-
tant differences outlined above, these two data
sets are not directly comparable for establishing
exposure trends over time. Future NHANES
data will be useful in establishing time trends.
BPA geometric mean concentrations were
signiﬁcantly lower in the afternoon collection
than in the morning and evening collections;
urinary concentrations between the morning
and evening sessions were not signiﬁcantly dif-
ferent. Consumption of food, believed to be a
major source of exposure to BPA (Kang et al.
2006; Vandenberg et al. 2007), during the day
may result in elevated BPA concentrations in
the evening collection samples. In children and
adolescents, however, the geometric mean con-
centrations of BPA did not vary signiﬁcantly
with the time of day of sample collection.
These observed variations in the geometric
mean concentrations of BPA depending on the
time of day of sample collection [Figure 1;
Supplemental Material, Table 2 (online at
http://www.ehponline. org/members/2007/
10753/suppl.pdf)] may reflect variability in
exposures as a result of differences in factors
such as diet, lifestyle, and use of products con-
taining BPA that may contribute to the
observed urinary concentrations of BPA.
Calafat et al.
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Figure 1. Geometric mean urinary concentrations
of BPA (µg/L) for each daily examination period.
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concentrations of BPA (4.5 µg/L) than adoles-
cents (3.0 µg/L) and adults (2.5 µg/L), and
adolescents also had significantly higher
LSGM concentrations than adults (all p-values
< 0.005; Table 4). Similarly, in a small study
conducted in the United States, the median
concentrations of BPA urinary species were
lower in 23 adults (0.47 µg/L) than in nine
9-year-old girls (2.4 µg/L) (Liu et al. 2005);
the BPA concentrations in these nine girls
were comparable to the geometric mean con-
centrations in a group of 90 girls 6–9 years of
age [2.0 µg/L (3 µg/g creatinine)] in three
locations in the United States (Wolff et al.
2007). Higher urinary concentrations in chil-
dren than in adults have been reported for
other nonpersistent chemicals, such as phtha-
late metabolites and organophosphate pesti-
cides (CDC 2005). The higher concentrations
of BPA in children may be explained by their
higher food consumption and air inhalation in
relation to their weight than those of adoles-
cents or adults. The differences also could be
related to differences in absorption, distribu-
tion, metabolism, or excretion of BPA.
Nevertheless, our ﬁndings highlight the need
for additional research to identify the sources
and routes of exposure to BPA, especially in
children, and the need for epidemiologic stud-
ies to target health outcomes related to BPA
exposures in children.
Among the NHANES 2003–2004 partici-
pants examined, females had significantly
higher (p = 0.043) LSGM concentrations of
BPA than males (Tables 3 and 4). These differ-
ences may reﬂect not only differences in expo-
sure but also differences in pharmacokinetic
factors; however, the relevance of these factors is
unknown. Furthermore, data are limited
regarding the association between BPA concen-
trations and sex (Kim et al. 2003; Takeuchi and
Tsutsumi 2002; Yang et al. 2006). The LSGM
concentrations in males and females reported
here (Table 3) are similar to those reported
among 30 healthy Korean adults (50% men)
(Kim et al. 2003). Although the total urinary
concentrations of BPA in the Korean men
(2.82 ± 0.73 µg/L) and women (2.76 ± 0.54
µg/L) were similar, men had significantly
higher (p < 0.01) concentrations of BPA-
glucuronide than women, and women had sig-
niﬁcantly higher (p < 0.01) concentrations of
BPA-sulfate than men (Kim et al. 2003). In
addition, no sex-related differences were
reported in another study involving 160
Korean adults, 81 of them men (Yang et al.
2006), but urinary concentrations of BPA uri-
nary species both in men and women were con-
siderably higher than concentrations reported
for NHANES 2003–2004 participants.
We also observed differences in LSGM
concentrations of BPA by race/ethnicity and
household income (Tables 3 and 4). Mexican
Americans had signiﬁcantly lower LSGM con-
centrations of BPA than non-Hispanic whites
and non-Hispanic blacks; no statistically sig-
niﬁcant differences exist between the LSGM
concentration of non-Hispanic whites and
non-Hispanic blacks. Participants in the low
household income category had significantly
higher LSGM concentrations than those with
the high household income (Tables 3 and 4).
These data suggest that race/ethnicity and
household income may be associated with
factors that affect exposure to BPA. 
In summary, we report here the first
nationally representative population-based
total BPA and tOP concentrations for the
U.S. population. These data are a baseline to
which concentrations of these chemicals in
future sampling of the population can be
compared to identify exposure trends. Our
data suggest that exposure to BPA in the
United States is widespread. We found signif-
icant differences in BPA concentrations across
selected demographic and income groups.
These findings highlight the need for addi-
tional research to identify sources and path-
ways of human exposure to BPA and to
evaluate potential health effects that may
result from human exposures to BPA.
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